Alembic Pharma Receives USFDA Approval for Generic Carbamazepine Tablets

rapid Summary

• Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its generic version of Carbamazepine extended-release tablets.
• The approved strengths are 100 mg, 200 mg, and 400 mg, therapeutically equivalent to Tegretol-XR tablets by novartis Pharmaceuticals Corporation.
• Carbamazepine extended-release tablets are used for treating seizures and nerve pain such as trigeminal neuralgia.
• According to IQVIA data, the estimated market size for this product in the US is USD 71 million (12 months ended March 2025).

Indian Opinion Analysis

Alembic Pharmaceuticals’ FDA approval signifies India’s growing prowess in generic pharmaceutical production.This development underscores India’s ability to compete in highly regulated markets like the US. The therapeutic relevance of Carbamazepine extended-release tablets, coupled with their considerable market size ($71 million), presents a significant possibility for Alembic to strengthen its international footprint. This could also boost innovation and investment within India’s pharmaceutical sector. However, it reflects the ongoing global reliance on affordable generics-something india has consistently excelled at delivering.

Read More